Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of PIKA Rabies Vaccine
NCT02657161Phase 1Completed
- Sponsor
- LakeShore Biopharma Co., Ltd
- Start
- Feb 2015
- Primary completion
- Jul 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PIKA rabies vaccine in rabies (3 arms), sponsored by LakeShore Biopharma Co., Ltd. Primary endpoints: Identification of any adverse events at 42 days and Titer level of Rabies Virus Neutralizing Antibody at Day 42. Started Feb 2015; status: completed.
02
Drugs
PIKA rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on NCT02657161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657161.